VIPR1

VIPR1 (Vasoactive Intestinal Peptide Receptor 1) is a protein that in humans is encoded by the VIPR1 gene. It is a member of the G protein-coupled receptor superfamily. This receptor is also known as the VPAC1 receptor, due to its ability to bind both vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP).

Function

The VIPR1 receptor is activated by the neuroprotective and immunomodulatory peptide VIP and the related molecule PACAP. Upon activation, the receptor stimulates adenylate cyclase activity and increases the production of cyclic AMP, a key second messenger involved in cellular signaling. This leads to the activation of protein kinase A (PKA), which can regulate gene expression and affect cellular proliferation and differentiation.

Clinical significance

Alterations in VIPR1 function have been implicated in a variety of diseases. For example, overexpression of VIPR1 has been observed in certain types of cancer, including breast cancer and prostate cancer. In contrast, reduced VIPR1 signaling may contribute to the pathogenesis of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

Therapeutic potential

Given its role in cellular proliferation and differentiation, VIPR1 is considered a potential therapeutic target for a variety of conditions. For instance, VIPR1 agonists could potentially be used to treat neurodegenerative diseases, while VIPR1 antagonists might be useful in the treatment of certain cancers.

See also

• Vasoactive intestinal peptide
• G protein-coupled receptor
• Adenylate cyclase
• Protein kinase A

References

This GPCR-related article is a stub. You can help WikiMD by expanding it.